Trial Profile
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of Combined Therapy With ATR Inhibitor AZD6738 and Gemcitabine, Using a Model Based Design
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms ATRiUM
- 10 Apr 2021 Study design presented at the 112th Annual Meeting of the American Association for Cancer Research
- 09 Oct 2019 Status changed from not yet recruiting to recruiting.
- 15 Jul 2019 Planned number of patients changed from 50 to 55.